Advanced search
Publication Cover
Pain Management Volume 2, 2012 - Issue 4
Submit an article Journal homepage
81
Views
0
CrossRef citations to date
0
Altmetric
Review

Buprenorphine Implant for Opioid Addiction

Walter Ling* Department of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 1640 S. Sepulveda Blvd, Suite 120, Los Angeles, CA90025-7535, USA. [email protected]View further author information
Pages 345-350 | Published online: 02 Aug 2012

References

  • Fiellin DA . The first three years of buprenorphine in the United States: experience to date and future directions. J. Addict. Med.1(2) , 62–67 (2007).
  • Ducharme S , FraserR, GillK. Update on the clinical use of buprenorphine: In opioid-related disorders. Can. Fam. Physician58(1) , 37–41 (2012).
  • Kraus ML , AlfordDP, KotzMM et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J. Addict. Med. 5(4) , 254–263 (2011).
  • Sullivan LE , ChawarskiM, O‘ConnorPG, SchottenfeldRS, FiellinDA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend.79(1) , 113–116 (2005).
  • Ling W , CasadonteP, BigelowG et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 304(14) , 1576–1583 (2010).
  • Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 043939. Substance Abuse and Mental Health Services Administration, MD, USA (2004).
  • Wesson DR , LingW. The clinical opiate withdrawal scale (COWS). J. Psychoactive Drugs35(2) , 253–259 (2003).
  • Tompkins DA , BigelowGE, HarrisonJA, JohnsonRE, FudalaPJ, StrainEC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend.105(1–2) , 154–159 (2009).
  • Chiang CN , HawksRL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend.70(Suppl.) , S39–S47 (2003).
  • Kuhlman JJ Jr, Levine B, Johnson RE, Fudala PJ, Cone EJ. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction93(4) , 549–559 (1998).
  • Umbricht A , HuestisMA, ConeEJ, PrestonKL. Effects of high-dose intravenous buprenorphine in experienced opioid abusers J. Clin. Psychopharmacol.24(5) , 479–487 (2004).
  • Walsh SL , PrestonKL, BigelowGE, StitzerML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther.274(1) , 361–372 (1995).
  • White J , BellJ, SaundersJB et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 103(1–2) , 37–43 (2009).
  • McCance-Katz EF , MoodyDE, MorseGD et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 43(Suppl. 4) , S224–S234 (2006).
  • Anchersen K , ClausenT, GossopM, HansteenV, WaalH. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction104(6) , 993–999 (2009).
  • Baker JR , BestAM, PadePA, McCance-KatzEF. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann. Pharmacother.40(3) , 392–396 (2006).
  • Carrieri MP , VlahovD, DellamonicaP et al. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend. 60(1) , 51–54 (2000).
  • Moatti JP , CarrieriMP, SpireB, GastautJ, CassutoJP, MoreauJ. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS14(2) , 151–155 (2000).
  • Kraft WK , DysartK, GreenspanJS, GibsonE, KaltenbachK, EhrlichME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addiction106 , 574–580 (2011).
  • Unger A , JagschR, JonesH et al. Randomized controlled trials in pregnancy: scientific and ethical aspects. Exposure to different opioid medications during pregnancy in an intra-individual comparison. Addiction 106(7) , 1355–1362 (2011).
  • Jones HE , KaltenbachK, HeilSH et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N. Engl. J. Med. 363(24) , 2320–2331 (2010).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.